Series A first close · Healthtech
THE PHAGE closes ¥570m Series A first round with equity and loans
ITOCHU Technology Ventures leads financing as the Japanese company broadens its preventive-health business.
The round brings new shareholders Tokio Marine & Nichido Fire Insurance and Fukui Capital Partners alongside returning backers Genesia Ventures and Vision Incubate. Shoko Chukin provides lending within the combined total.
An accompanying alliance with Tokio Marine Holdings will explore healthcare services across the insurance group, including prevention of worsening lifestyle-related disease. It gives THE PHAGE a potential route from research and pilot work into wider commercial use.
Use of funds
Expand Glucose Flight personalized prevention services in Japan and overseas.
Develop the continuous glucose foundation model and recruit specialist staff.
Funding history
Series A first close · This round¥570M